

IFW



PATENT
Customer No. 60,949
Attorney Docket No. 08702.0097-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Yannoni et al.) Group Art Unit: 1653
Application No.: 10/523,014) Examiner: Monshipouri, Maryam
Filed: February 1, 2005)
For: MK2 Interacting Proteins) Confirmation No.: 2654

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before a first Office Action on the merits.

Copies of the listed non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law,

Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 27, 2007

By: 
James P. Kastenmayer
Reg. No. 51,862

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number 10/523,014 Filing Date February 1, 2005 First Named Inventor Yannoni Art Unit 1653 Examiner Name Monshipouri, Maryam	 JUN 27 2007
Sheet	1	of	2	Attorney Docket Number 08702.0097-00000	



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NONPATENT LITERATURE DOCUMENTS

Examiner Initials ^a	Cite No. ^b	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ^c
		Upton, J., "California's non-profit community blood bank system," California Medical Association, 73: 1950-52 (1950).	
		Plath, K., et al., "Characterization of the proline rich region of MAPKAP kinase 2: influence on catalytic properties and binding to the C-ABL SH3 domain in vitro," Biochemical and Biophysical Research Communications, 203: 1188-94 (1994).	
		Supplementary partial European Search Report, mailed May 23, 2007	
		Honma, S., et al. "The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells," Endocrine Journal, 49: 371-77 (2002).	
		Yannoni, Y., et al., "P66 ^{sch} A interacts with MAPKAP kinase 2 and regulates its activity," FEBS Letters, 564: 205-11 (2004).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.